Martin Bradstreet
Investor & Programmer, Former Poker Player
Personalis no longer offers the hoped-for path to a Tempus stock swap, because its premium to the Tempus deal price makes a knockout cash offer the likelier outcome if the deal breaks. Tempus, Merck and other deal supporters own much of the equity, so a rival bid would need to be undeniably better and would probably be cash, nullifying the reason to hold even at a higher price. Biodesix looks more discounted, with 82% gross margins, 35% growth and a valuation below 3x revenue. x.comÂ
Personalis is still a great spot because it now trades essentially as Tempus AI under their deal, and Tempus looks somewhat likely to make a major move higher at some point. Tempus itself is the better holding, a key company in the biodiagnostics theme; for Personalis holders the deal is unappealing versus owning Tempus, which gets all the upside and none of the downside. @MathHashtag asks whether Personalis is capped at about 16% upside until the deal closes. x.com x.com x.comÂ
Tempus AI's deal for Personalis has some protection, though it is not guaranteed. There is a $78.6 million termination fee, and Merck, which owns 14 million Personalis shares, voted for the merger on July 20. The risk is higher now that Personalis trades above the buyout price, especially if another bidder appears. x.comÂ
Tempus AI's $1.5B all-stock acquisition of Personalis is smart long-term positioning despite the dilution-driven dip. Owning Personalis's NeXT Personal MRD technology outright lets Tempus pair liquid-biopsy recurrence testing, one of oncology's fastest-growing areas, with its multimodal dataset and AI at scale. That extends Tempus from diagnostics into high-margin longitudinal monitoring and could strengthen its moat, though execution will decide it. x.comÂ
Personalis is rising because shareholders look increasingly likely to reject Tempus's takeover, not on hopes of a competing bid, so Craig-Hallum's downgrade misreads the move. Its Next platform will likely generate over $500 million of annual revenue, whatever Craig-Hallum says about the MRD market dwarfing Personalis's potential Moderna revenue. x.comÂ
Tempus AI's $1.5 billion all-stock acquisition of Personalis strengthens its position in precision oncology, adding Personalis' MRD platform, expanding its AI-driven diagnostics business and widening its opportunity in a market estimated at about $20 billion. The 6% drop on the news reflects dilution, timing ahead of earnings and near-term integration risk, a classic case of short-term dilution overshadowing long-term strategy. x.com x.comÂ
Tempus AI's Personalis acquisition is a great strategic fit but raises the risk profile, because Tempus overpaid. Personalis adds longitudinal molecular-response and patient-outcome data that reinforce Tempus's data moat. But at roughly 19 times Personalis's guided 2026 revenue, with 15-20% gross margins and about $100M of cash burn, it adds burn on top of Tempus's own and could take years to become accretive. The thesis needs many years of patience and near-flawless execution. x.com x.comÂ
Personalis can ramp colorectal cancer MRD testing aggressively once it secures reimbursement, and @subhashperi reports its CRC filing is in. CRC is the largest segment of the MRD market, and until reimbursement Tempus cannot unlock its full sales capacity without draining Personalis's balance sheet. x.comÂ
Tempus AI's growth story has become a real one, with Q2 revenue up 22% to $382.5 million, positive net income and EBITDA, a 73.5% gross margin and $816 million of cash. Its $1.5 billion Personalis deal owns the sequencing technology behind the Moderna-Merck mRNA cancer vaccine, whose strong Phase 3 melanoma results validated the bet. Piper Sandler upgraded it to Overweight with a $76 target, up from $56, citing Personalis and strong INTerpath-001 MRD data. $80 is support for the breakout. x.comÂ
Tempus AI's selloff after it beat and raised guidance looks like a great deal, and a further drop would be a chance to buy more. x.comÂ
Personalis could be a swing trade on breakthrough cancer vaccine news, a holy grail whose importance is hard to overstate. Downstream players in mRNA cancer vaccines may have some juice. x.com x.comÂ
Tempus AI is a short idea because the stock is being pumped on recent FDA clearances for its EKG-AI tools, while the revenue from them is far off and may never materialize. x.comÂ
